CTRI/2012/09/003000已完成4 期
A Randomized, open label, comparative, parallel group, three-arm study to evaluate the efficacy, safety and tolerability ofa combination of clobetasol, neomycin and miconazole versus combination of betamethasone, clotrimazole, neomycin versus combination of betamethasone, gentamicin, miconazole in patients with any type of eczematous disorderassociated with underlying tinea / yeast infection
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients aged 18 years and above diagnosed with any type of eczematous disorder associated presenting clinical features of underlying tinea/yeast infection
- •Patients who agree to adhere to the study design
- •Patients who give their consent for participation in this study
排除标准
- •Pregnant or lactating females
- •Indications for use of systemic therapy
- •Patients sensitive to corticosteroids
- •Patients who have immune deficiency, hepatic or renal impairment
- •Patients who have been on any therapy within 1 month prior to enrollment in the study
- •Patients who are using any other concomitant therapy
研究者
相似试验
已完成
2 期
Effect of NiKu plus in reducing fever.CTRI/2018/09/015775Dr JRKs Research and Pharmaceuticals Pvt Ltd34
已完成
3 期
A Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Lubiprostone Soft Gelatin capsules 24 mcg Vs Bisacodyl tablet 10 mg in the patients with chronic constipation.CTRI/2010/091/000586Ajanta Pharma Ltd200
Unknown
3 期
A clinical study to evaluate the efficacy, safety and tolerability of Rosuvastatin 10 mg plus Fenofibrate 160 mg tablet Vs Atorvastatin 10 mg plus Fenofibrate 160 mg Tablet in patients with dyslipidaemia.CTRI/2010/091/001294Ajanta Pharma Ltd200
尚未招募
3 期
A clinical trial to study the efficacy and safety of Budesonide Dry Powder Inhaler Rotacaps in Patients with Mild to Moderate Asthma.CTRI/2011/06/001788Inventia Healthcare Private Limited20
已完成
4 期
Study to examine the body response of Peg-filgrastim against Neulasta® along with Chemical agent in Patients with Breast Cancer who will be selected in any order to a known treatment.CTRI/2018/02/011914upin Limited Biotechnology Division138